Source: ASM

A patient presents with a bacterial infection that does not respond to standard antibiotics: a lock that modern medicine can't open. But somewhere in the world, there may exist a key: a bacteriophage capable of targeting that exact pathogen with precision.

This remarkable specificity arises from how phages recognize and bind to bacteria. Each phage carries proteins on its surface that interact with distinct bacterial structures (e.g., receptors). Because these receptors vary widely between bacterial species and even strains, a given phage typically infects only a narrow range of hosts. This high degree of selectivity is a double-edged sword: while this precision spares beneficial microbes, it underlies a key challenge for phage therapy: identifying the precise phage that matches the “lock” presented by a patient's infection.

Today, phage therapy in the United States operates more like a global scavenger hunt than a coordinated system. Steffanie Strathdee, who delivered the Science and Society lecture at ASM Microbe 2026, likens phage hunting to " … having a million locks spread all over the world and not knowing which keys match."

• Physicians are "lock collectors." They encounter patients with complex, often drug-resistant infections and bring those “locks” forward, hoping for a solution.
• Phage researchers and library developers are “key collectors.” Around the world, they isolate, characterize and store phages—each with the potential to unlock a specific infection.

But here's the problem: these locks and keys are scattered across institutions, countries and databases with no unified system to connect them.

As a result, matching a patient to the right phage often relies on personal networks, academic collaborations and a dash of serendipity. This approach is not scalable, equitable or fast enough for critically ill patients.

Transitioning From Chance to Coordination

What if, instead of relying on chance, we had a central matchmaking system? A system designed to not only store locks and keys, but also to classify, match and deploy them efficiently.

(Click image to view larger version.)

Source: ASM

This is where the American Society for Microbiology (ASM) Health Unit is stepping in. ASM has launched the Phage Therapy Coordination Network, with the goal of systematizing how locks and keys are paired.

This central matchmaking platform would orchestrate 4 critical components:

(Click on image to view larger version.)

Source: ASM

1. Classifying the Locks and Keys

Before you can match a key to a lock, you need to understand the specific attributes of the locks and keys relevant to making the match.

Today, infections are described inconsistently across labs and clinical settings. ASM aims to launch working groups to develop standardized methods for characterizing bacterial infections and phages.

This ensures that every lock and key that is logged into the system is described in a common language, making it searchable and comparable.

2. Predicting the Right Key

Rather than testing phages against bacteria 1-by-1, ASM is launching a working group to integrate predictive AI-driven algorithms into the matchmaking platform.

These tools would leverage genomic and phenotypic data against the known phage-host interactions to predict which phages are most likely to work in silico, before lab testing.

This represents a crucial shift from trial-and-error to data-driven precision, dramatically improving the speed and success rates of phage hunting.

3. A Shared Platform for Lock and Key Collectors

Right now, phage libraries operate in institutional silos.

ASM’s vision includes a centralized platform where:

• New clinical cases (locks) are visible to phage developers.
• Available phages (keys) are discoverable across institutions.
• Stakeholders can collaborate on matching and validation in real-time.

This creates a dynamic market to facilitate real-time supply and demand connections.

4. Reliable Delivery: Getting the Key to the Lock

Finding the right phage is only half the battle because even the perfect key is useless if it can’t reach the lock when it matters most. Manufacturing, regulatory submission and clinical deployment are also key bottlenecks.

ASM is launching working groups to develop consensus statements for:

• Phage manufacturing per standardized processes, specifications and quality controls.
• Regulatory documentation templates to support FDA use per IND pathway.
• Clinical use of phage therapy, including patient selection, dosing and therapeutic monitoring.

Why This Matters Now

The rise of antimicrobial resistance is turning more infections into "locks" that traditional antibiotics can no longer open. Phage therapy offers a powerful solution, but only if we can operationalize it at scale. Without coordination, we risk delaying treatment for patients left with no other options, underutilizing existing phage resources and failing to build the evidence base needed for broader adoption.

ASM's Phage Therapy Coordination Network is committed to building the patient-phage matchmaking platform, transforming phage therapy from a fortunate coincidence into a reliable clinical strategy. With this level of coordination, we can unlock faster time-to-treatment and a larger volume of phage therapy cases.